Evidence map›Paper›PMID 40085431›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2025

HLA-E/peptide complexes differentially interact with NKG2A/CD94 and T cell receptors.

Linda Voogd, Remco L van den Broek, Marjolein van Wolfswinkel, Kees L M C Franken, Paula Ruibal, Willem Jespers, Judith Leitner, Peter Steinberger, Gerard J P van Westen, Tom H M Ottenhoff and 1 more

Abstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Diagnostics (Basel, Switzerland) · 2026
    Article
  3. Unconventional CD8Science advances · 2025
    Article
  4. Article
  5. NK Cells: A Powerful Squad Versus SARS-CoV-2.International journal of molecular sciences · 2025
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Linda VoogdLeiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-0523-8929
Remco L van den BroekDivision of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.ORCID 0009-0008-5661-1157
Marjolein van WolfswinkelLeiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0003-4952-9709
Kees L M C FrankenLeiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
Paula RuibalLeiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0003-3217-4497
Willem JespersDivision of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.ORCID 0000-0002-4951-9220
Judith LeitnerCentre for Pathophysiology, Infectiology and Immunology, Institute of Immunology, Medical University of Vienna, Vienna, Austria.
Peter SteinbergerCentre for Pathophysiology, Infectiology and Immunology, Institute of Immunology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-6848-4097
Gerard J P van WestenDivision of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.ORCID 0000-0003-0717-1817
Tom H M OttenhoffLeiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0003-3706-3403
Simone A JoostenLeiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-9878-0863

Funding

HLA-E restricted T-cell immunity in Mycobacterium tuberculosis infectionR01AI141315 · NIAID · LEIDEN UNIVERSITY MEDICAL CENTER · PI JOOSTEN, SIMONE ANNE · 2019 to 2022
$1.7M
Dutch National Growth Fund NGFOP2201National Institute of Allergy and Infectious DiseasesNIAID NIH HHS R01 AI141315NIH HHS R01AI141315
6 · The paper itself

Abstract

The virtually monomorphic antigen presentation molecule HLA-E can present self- and non-self peptides to the NKG2A/CD94 co-receptor inhibitory complex expressed on natural killer (NK) cells and to T cell receptors (TCRs) expressed on T cells. HLA-E presents self-peptides to NKG2A/CD94 to regulate tissue homeostasis, whereas HLA-E restricted T cells mediate regulatory and cytotoxic responses toward pathogen-infected cells. In this study, we directly compared HLA-E/peptide recognition and signaling between NKG2A/CD94 and 2 HLA-E restricted TCRs that can recognize self-peptides or identical peptide mimics from the viral UL40 protein of cytomegalovirus using position substituted peptide variants. We show that position 7 is critical for interaction with NKG2A/CD94, whereas position 8 is important for interaction with the TCRs. The Arginine at position 5 of these peptides is an essential residue for recognition by both receptors. Thus, NKG2A/CD94 and TCRs have different requirements for recognition of peptides presented in HLA-E.

Indexed as

Histocompatibility Antigens Class INK Cell Lectin-Like Receptor Subfamily CNK Cell Lectin-Like Receptor Subfamily DPeptidesReceptors, Antigen, T-CellAntigen PresentationCytomegalovirusHLA-E AntigensHumansKiller Cells, NaturalProtein BindingHistocompatibility Antigens Class IHLA-E AntigensKLRC1 protein, humanKLRD1 protein, humanNK Cell Lectin-Like Receptor Subfamily CNK Cell Lectin-Like Receptor Subfamily DPeptidesReceptors, Antigen, T-CellHLA-ENKG2A/CD94peptide/receptor interactionsT cell receptor

Identifiers

PMID40085431
PMCPMC12041767

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.